The variability in beta-cell function in placebo-treated subjects with type 2 diabetes: application of the weight-HbA1c-insulin-glucose (WHIG) model by Duong, J.K. (Janna) et al.
 This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/bcp.13144 
 
This article is protected by copyright. All rights reserved. 
The variability in beta-cell function in placebo-treated subjects with type 2 diabetes: 
Application of the Weight-HbA1c-Insulin-Glucose (WHIG) Model 
J K Duong
1,2,3
, W de Winter
4
, S Choy
5
, N Plock
6
, H Naik
6,7
, W Krauwinkel
8
, S A G Visser
9
, 
K M Verhamme
1
, M C Sturkenboom
1
, B H Stricker
9
, M Danhof
2
. 
1
Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, The Netherlands; 
2
Leiden Academic Centre for Drug Research (LACDR), Division of Pharmacology, Leiden 
University, Leiden, The Netherlands;
 3
Faculty of Pharmacy, The University of Sydney, 
Sydney, Australia; 
4
Janssen Prevention Center, Leiden, The Netherlands; 
 5
Department of 
Pharmaceutical Biosciences, Pharmacometrics Research Group, Uppsala University, 
Uppsala, Sweeden;
6
Global Pharmacometrics, Takeda Pharmaceuticals International, Zurich, 
Switzerland and Deerfield, USA;
 7
Quantitative Pharmacology, Biogen, Cambridge, USA; 
8
Global Clinical Pharmacology and Exploratory Development, Astellas Pharma Europe BV, 
Leiden, The Netherlands; 
9
Early Stage Quantitative Pharmacology & Pharmacometrics, 
Merck, Upper Gwynedd, USA;
9
Department of Epidemiology, Erasmus Medical Centre, 
Rotterdam, The Netherlands. 
Running title: Placebo treatment in subjects with type 2 diabetes 
Words: 4,666 
Figures: 3 
Tables: 4 
Keywords: type 2 diabetes mellitus, placebo treatment, semi-mechanistic modelling, beta-cell 
function, disease progression.  
  
This article is protected by copyright. All rights reserved. 
ABSTRACT  
Aim: The Weight-HbA1C-insulin-glucose (WHIG) model described the change in weight on 
insulin sensitivity (IS) in newly-diagnosed, obese subjects receiving placebo treatment. This 
model was applied to a wider population of placebo-treated subjects to investigate factors 
influencing the variability in IS and -cell function. 
Methods: The WHIG model was applied to the WHIG dataset (Study 1) and two other 
placebo datasets (Studies 2 and 3). Studies 2 and 3 consisted of non-obese subjects and 
subjects with advanced T2DM. Body weight, fasting serum insulin (FSI), fasting plasma 
glucose (FPG) and HbA1c were used for non-linear mixed effects modelling (software, 
NONMEM v7.2). Sources of inter-study variability (ISV) and potential covariates (age, sex, 
diabetes duration, ethnicity, compliance) were investigated.  
Results: An ISV parameter for baseline parameters (body weight and -cell function) was 
required. The baseline -cell function was significantly lower in subjects with advanced 
T2DM (Study 2: median difference, 15.6%, P<0.001; Study 3: 22.7%, P<0.001) than subjects 
with newly-diagnosed T2DM (Study 1). A reduction in the estimated insulin-secretory 
response in subjects with advanced T2DM was observed but diabetes duration was not a 
significant covariate. 
Conclusion: The WHIG model can be used to describe the changes in weight, IS and -cell 
function in the diabetic population. IS remained relatively stable between subjects, however 
large inter-subject variability in the -cell function was observed. There was a trend towards 
decreasing -cell responsiveness with diabetes duration, and further studies incorporating 
subjects with a longer history of diabetes is required. 
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 
 Type 2 diabetes mellitus (T2DM) has a very slow disease progression, which is 
associated with the gradual decline in β-cell function.  
 The Weight-HbA1c-Insulin Glucose (WHIG) model described the effects of placebo 
treatment on β-cell function and insulin sensitivity in newly-diagnosed, obese subjects 
with T2DM 
 It is not known whether the WHIG model can be applied to a wider population of 
people with T2DM. 
 
WHAT THIS STUDY ADDS 
 The WHIG model described the disease progression of T2DM in a wider population 
of subjects with T2DM including subjects with advanced T2DM. 
 The variability in the insulin sensitivity was small, but there was large inter-individual 
variability in β-cell function. 
 Diabetes duration was not a significant covariate for the β-cell parameters but a trend 
towards lower β-cell function with diabetes duration was observed. 
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INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is characterized by hyperglycaemia due to insulin 
resistance and pancreatic -cell dysfunction. If T2DM is left untreated, people with T2DM 
are at risk of developing many microvascular and macrovascular complications [1]. However, 
it is the continued deterioration in -cell function that undermines the long-term effectiveness 
of many antidiabetic drugs to maintain euglycemia [2]. Therefore, it is not surprising that the 
goal in the treatment of T2DM has shifted from maintaining euglycaemia to delaying the 
progression of the disease by restoring or slowing the decline in -cell function [3, 4].  
The function of pancreatic -cells cannot be measured directly and methods to assess 
the changes in -cell function are required. The pancreatic -cells respond to high glucose 
concentrations by increasing the release of insulin from the pancreas. Therefore, the 
concentrations of fasting serum insulin (FSI) and fasting plasma glucose (FPG) can be used 
to reflect the balance between hepatic glucose output and insulin secretion, maintained by a 
feedback loop between the liver and the -cells [5]. This relationship can be described 
mathematically using the model of homeostasis (HOMA) to estimate the -cell function and 
insulin sensitivity in people with T2DM [5, 6].  
There are two semi-mechanistic models that had utilized the homeostatic relationship 
between FSI and FPG. The de Winter model [7] was first developed to describe the 
progression of T2DM in subjects treated with either metformin, gliclazide or pioglitazone.  
Glycosylated haemoglobin (HbA1c), a marker of glucose exposure over 3 months, was also 
described in the model using a feed-forward mechanism between FPG and HbA1c. This 
model was recently updated to the Weight-HbA1c-Insulin-Glucose (WHIG) model to include 
the effect of weight on insulin sensitivity in placebo-treated subjects [8, 9]. In this study, the 
change in body weight was found to be a driver of insulin sensitivity, whereby a median 
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weight loss of 4.1 kg was associated with a 30% increase in insulin sensitivity [8]. 
Furthermore, the HbA1c model was expanded to include three transit compartments, to 
reflect the lifespan of the glycated red blood cells [8].  
The WHIG model has only been evaluated in newly-diagnosed, obese subjects who 
entered a weight loss program. These subjects only represent a subset of the entire diabetic 
population and it is not known whether this model can be used to describe the changes in 
weight, insulin sensitivity and -cell function in the wider diabetic population. Therefore, the 
aim of this study was to investigate the use of the WHIG model in a wider population of 
placebo-treated subjects with T2DM and to examine factors that may influence the variability 
in the parameter estimates. 
 
METHODS 
Datasets 
Data from placebo arms of 3 clinical trials in patients with T2DM were used in this study, 
including the dataset used to build the WHIG model (Study 1, [8]). The data was obtained 
from placebo arms of randomized, double blind, multi-centre, placebo-controlled Phase 2/3 
clinical trials. The study design of the placebo arms are described in Table 1. Study 1 
included a weight loss component, whilst subjects from Studies 2 and 3 were maintained on a 
stable diet and exercise regimen. The study was conducted according to International 
Conference on Harmonization Good Clinical Practice guidelines, and applicable laws and 
regulations. Ethics approval was obtained from the institutional review board and informed 
written consent was obtained from each subject. The ClinicalTrials.gov identifier for these 
studies are NCT0023660 (Study 1), NCT01071850 (Study 2) and NCT01117584 (Study 3). 
  
This article is protected by copyright. All rights reserved. 
Study 1 (n = 181) included newly diagnosed, treatment naïve, obese subjects (BMI 
>27 kg/m
2
 and <50 kg/m
2
) to investigate the effect of diet and exercise on weight loss and 
glucose control. Subjects first entered a 6-week placebo run-in before the placebo treatment 
phase (placebo treatment). These subjects were followed for up to a total of 66 weeks. 
Study 2 consisted of treatment naïve subjects (n = 29) and subjects who were 
previously treated with an antidiabetic drug (n = 37). Subjects who were previously treated, 
entered a 6-week washout phase, followed by a placebo run-in phase (2 weeks) and placebo 
treatment phase (12 weeks). Treatment naïve subjects only entered the placebo run-in phase 
and placebo treatment phase.  
Study 3 (n = 65) included subjects who were inadequately controlled on metformin 
(1500 mg daily, HbA1c >7%) for at least 6 weeks prior to the start of the study. In contrast to 
Study 2, these subjects did not enter a washout phase prior to the start of the study. This study 
also consisted of a 2-week placebo run-in followed by a 12-week placebo treatment phase 
(placebo treatment). 
 
Measurements of Weight, FSI, FPG and HbA1c 
The timing and frequency of weight measurements and the collection of FSI, FPG and 
HbA1c samples are shown in Supplementary Table S1 and Supplementary Table S2. In all 
studies, weight was measured at every clinic visit. For Study 1, up to 22 weight 
measurements were recorded, whilst Studies 2 and 3 had 7 measurements of weight from 
each subject.  
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FSI was measured less frequently than the other glycemic markers. In Study 1, there 
were up to 4 observations of FSI for each subject. Similarly, 5 observations of FSI were 
recorded from each subject in Studies 2 and 3. In Study 1, there were 18 measurements of 
FPG and 19 measurements of HbA1c from each subject. In Studies 2 and 3, there were 7 FPG 
observations and 6 HbA1c measurements from each patient. Subjects were previously treated 
with antidiabetic drugs in Study 2, entered a 6-week washout phase prior to the start of the 
study. These subjects had an additional measurement of weight, FSI, FPG and HbA1c at 6 
weeks prior to the start of the study. 
 
The WHIG model 
The WHIG model [8] is shown in Supplementary Figure 1. This model consisted of a 
turnover model for body weight, a closed form solution for FSI and FPG with steady-state 
assumptions, and three transit compartments for HbA1c [8]. The equations relevant to this 
study (treatment effects, insulin sensitivity and β-cell function) are outlined below. The 
glucose-insulin homeostasis was modelled as a feedback mechanism between FSI and FPG 
and these equations are shown in Supplementary (NONMEM control stream). 
 
Dynamics of body weight 
A turnover model was used to describe the dynamics of body weight (Supplementary Figure 
S1). The effects of diet and exercise counselling and placebo treatment on body weight were 
modelled as two step-functions: a treatment effect of diet and exercise counselling at 
screening (        ) and a placebo treatment effect at the start of placebo treatment phase 
(      t > placebo run-in phase).      and      were expressed as a relative change from 
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baseline. The treatment effects of placebo, diet and exercise, however, can wear off with 
time. A linear rate of loss function (      ) was added to describe the wearing off of 
treatment effects with time (Eq. 1). The net treatment effect on body weight (   , Eq. 1) was 
modelled on the input side of the turnover model of body weight (Eq. 2). 
    
                 
   
 
              
 
      
   
                               
Eq. 1 
    
                                                                                           
Eq. 2 
where t is time in days.         
 
Insulin sensitivity (IS) 
The dynamics of insulin sensitivity (  ) is driven proportionally by the change in body 
weight (     . The effect of weight change on insulin sensitivity (   , Eq. 3) was scaled 
with a scaling factor (ScaleEFS): 
                                                             
Eq. 3 
     was calculated as the difference between the baseline weight and the current weight. 
At baseline (     ), the value of     is 1. A reduction in weight from baseline will increase 
insulin sensitivity (    >0), while an increase in weight will result in a decrease in insulin 
sensitivity (    <0). 
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The IS was then calculated using the estimated baseline insulin sensitivity as a logit function 
(  ): 
   
 
          
                Eq. 
4 
 
Dynamics of -cell function 
The dynamics of β-cell function was modelled as the result of two components: a disease 
progression component (BF) and a treatment effect (   ). BF is a logistic decay function to 
describe the natural deterioration in -cell function from baseline (Eq. 5). It consists of 
parameters to estimate the baseline β-cell function (    and the rate of β-cell decline per year 
from baseline (   : 
   
 
                      
        Eq. 
5 
where t is time in days.   , like     provides an indicator of the disease status of subjects at 
study entry. The parameter    can have either a positive or negative value to indicate either a 
decline in -cell function with time, or an improvement in -cell function over time.  
 In the WHIG model, the treatment effect,    , was estimated empirically and was 
modelled with a logistic increase and decline to describe the initial improvement and 
subsequent decline in the -cell function due to the effect of weight loss [8]. Since Studies 2 
and 3 were short trials, this treatment effect was simplified to a step function (Eq. 6):  
                                                                                                             Eq. 6 
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where      is the estimated treatment effect and     is a parameter to switch on the 
treatment effect. At baseline (t = 0),       to indicate no treatment effect (      . At 
    ,     takes the value of 1 to switch on the effect of placebo treatment on the -cell 
function.  
A limitation of using the step function is that the treatment effect remains constant throughout 
the duration of the study and changes in the treatment effect with time cannot be described. 
The overall effect of β-cell function on FSI production is a function of    and     (Eq. 7): 
                      Eq. 
7 
 
Dynamics of HbA1c 
There are three transit compartments for HbA1c. The first transit compartment is shown in 
Eq. 8 and the remaining transit compartments can be seen in the NONMEM control stream 
(Supplementary data). Postprandial glucose (PPG) was not measured, however it may 
contribute to the production of HbA1c in addition to FPG. The potential contribution of PPG, 
therefore was estimated. At t > 0, the effect of PPG was scaled by a scaling parameter 
(ScalePPG , Eq. 8).  
         
                                      –                                   
Eq. 8 
The mean transit time (MTT) of HbA1c is estimated and HbA1ckout was calculated as 
 
   
 .  
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Population analyses 
Population pharmacodynamic analyses were conducted using the population modelling 
package NONMEM® 7.2.0 (ICON Development Solutions, Hanover, MD, USA) [10] with 
first-order conditional estimation method with interaction (FOCE-I). Model development was 
managed using Perl-Speaks-NONMEM 3.5.3 [11], Pirana 2.8.1 [12] and R (Version 3.2.5) 
[13]. All observations were log-transformed prior to the analysis and residual variability was 
described with proportional error models for weight, FSI, FPG and HbA1c. The IIV for PPG, 
        , baseline WGT and residual error models were log-normally distributed, whilst all 
other parameters were assumed to be normally distributed. Since the structure of the model 
was already developed, the model building procedure included (1) exploratory data analysis 
and data exclusion, (2) sensitivity analyses, (3) covariate modelling and (4) model evaluation. 
1. Exploratory data analysis and data exclusion 
For Studies 2 and 3, some observations and subjects were excluded from the analyses to 
avoid bias. The reference range for FSI is below 25 mI U/L [14]. There was one outlying FSI 
observation of 343 mI U/L, indicating non-compliance with the fasting protocol. This FSI 
observation and the corresponding FPG were excluded from the analyses.  
There were two subjects who terminated the trial on the second visit (18 days) and 
three subjects with only one FSI observation. These individuals were excluded from the 
analyses. In total, only 1% of the original dataset was excluded to avoid bias in parameter 
estimates. After removing these observations, the median FSI of the dataset was 14.8 mI U/L 
(2.7 mI U/L – 99.8 mI U/L, range). 
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In one arm of Study 2, subjects entered a 6-week washout phase, however, there was 
only one observation collected during this phase. Therefore, observations during this phase 
were not used for model development. 
 
2. Sensitivity analyses 
Sensitivity analyses were conducted on various system-specific parameters that were 
considered difficult to estimate in Studies 2 and 3. β-cell function ( , Eq. 7) involves both 
estimating the natural decline in β-cell function from baseline (  , Eq. 5), which is 
counteracted with the positive treatment effect on β-cell function (   , Eq. 6). One of the 
main parameters that would be difficult to estimate is   , the rate of β-cell function decline 
from baseline. The effect of fixing the population estimate of    to a published value of 0.209 
[8] and estimating    was tested. 
Additionally, a sensitivity analysis was also conducted on    , the treatment effect on 
β-cell function, as it can confound the estimate of   . Subjects from Studies 2 and 3 did not 
enter a weight loss program, therefore estimates of     are likely to be small or insignificant 
to counteract the rate of disease progression (  ). The effect of removing     to improve the 
estimate of   was tested.  
Lastly, MTT was considered difficult to estimate due to the short trial duration of Studies 
2 and 3. Therefore, the effect of fixing MTT to a previously published value of 38.9 days [8] 
and estimating this parameter was tested.  
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3. Covariate modelling 
Potential covariate effects were identified by visual inspection of covariate plots against the 
empirical Bayes estimates (EBEs). Statistical significance was determined by stepwise 
inclusion into the model, and was guided by the objective function value (OFV, -2log 
likelihood), whereby a significance level of P <0.01 was considered statistically significant 
(corresponds to drop in OFV by 6.63 points with d.f.=1) [15]. The covariates investigated 
included age, sex, ethnicity, diabetes duration and compliance to placebo treatment (by pill 
count), for parameters describing the treatment effect (    ,     ,    ) and parameters 
describing the disease status (  ,   ,   ). The duration of diabetes was not known for subjects 
enrolled in Study 1, and therefore was assumed to be 1 year to enable testing diabetes 
duration as a covariate in the model.  
The potential covariate effect of diabetes duration was investigated visually using 
EBE plots vs diabetes duration for Studies 2 and 3. The disposition index was used to explore 
potential relationships between model-derived estimates of    and    with diabetes duration. 
The disposition index is the hyperbolic relationship between insulin sensitivity and beta-cell 
function (or insulin secretion), whereby a decrease in insulin sensitivity (high FPG) is 
compensated by an increase in -cell function to stimulate insulin release [16].  
The baseline values of body weight, FPG, FSI and HbA1c were tested as potential 
covariates on the parameters describing the treatment effect. The transformation of random 
effect parameters [17] were investigated for the random effect variables that were non-
normally distributed. 
Sources of inter-study variability (ISV) were investigated by inspecting plots of EBEs 
vs Study. Since Study 3 did not include a washout phase, it is possible that residual treatment 
effects of metformin continued in this placebo study. This was further investigated by testing 
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ISV as a fixed effect on baseline parameters (weight, FPG, FSI and HbA1c), on parameters 
describing the treatment effect (    ,     ,    ) and the disease status (  ,   ,   ).  
 
Model evaluation and statistical methods 
Model selection was guided by a significant drop in OFV (P <0.01), goodness-of-fit plots and 
visual predictive checks (VPCs). Model stability was assessed by the ability of the model to 
achieve a successful covariance step and a low condition number (<1000, [18]). The 
condition number is calculated as the square root of the ratio of the largest eigenvalue to the 
smallest eigenvalue of the correlation matrix to evaluate collinearity of the parameters [18]. 
The VPC of the final model was evaluated by comparing the 10
th
, 50
th
 and 90
th
 percentiles of 
the observations to the corresponding 10
th
, 50
th
 and 90
th
 percentiles of the simulations (n = 
1000) [19]. 
Significant differences between baseline measurements were evaluated using the 
unpaired t test in R. A P value of <0.001 was considered statistically significant. 
 
RESULTS 
Characteristics of the subjects 
The demographics of the subjects from each study are shown in Table 2. There were 
significant differences in the body weight distribution for all 3 studies (Figure 1). Subjects 
from Study 1 had a higher baseline body weight compared to Study 2 (median difference 24.1 
kg) and Study 3 (median difference 14.8 kg). The distribution of height and BMI, however, 
was comparable between studies. At baseline, the insulin-to-glucose ratio was lower in 
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Studies 2 and 3  compared to Study 1 (Table 2, Figure 1), indicating that subjects from 
Studies 2 and 3 had a poorer β-cell function. Furthermore, subjects enrolled in Study 3 had a 
longer duration of diabetes than Study 2 (median difference 3.1 years). 
  
Population model 
A total of 8587 observations from Study 1, 1526 observations from Study 2 and 1554 
observations from Study 3 were used for population pharmacodynamic modelling. Like the 
WHIG model, a full omega block (n = 10) was used to account for all correlations between 
parameters (Supplementary Table S3). The covariance between the residual error of FSI and 
FPG was also estimated. 
An ISV on weight was modelled to show a shift in the population mean for each 
study. From the base model, this was found to significantly improve the model (ΔOFV -88.03 
points). An ISV was also added for b0 (Study 1 vs Study 2 and 3), which was also significant 
(ΔOFV -88.9 points). The IIV for s0 was non-normally distributed and was transformed using 
the Box-Cox transformation [17] to improve the model (ΔOFV -44.2 points, P <0.001): 
    
         
         
      
                                                                                                         Eq. 9 
where     is the Box-Cox transformed random effect for   ,     is the normally distributed 
random effect and        is a parameter determining the shape of the distribution. Age, 
diabetes duration, sex, and ethnicity were not significant covariates for these baseline 
parameters. 
In the WHIG model, there were 2 treatment effects on weight at the placebo run-in 
phase and at the treatment phase. These treatment effects were kept for Study 1. The 
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additional placebo effect at the treatment phase for Studies 2 and 3, however, was not 
significant and was removed from the model. The lack of a washout phase in Study 3 did not 
influence the parameter estimates of treatment effects and disease status. There was an ISV 
added for baseline weight but this was also added for Study 2. 
Compliance to placebo pills was explored as a potential covariate on the treatment 
effects for weight (    ). For Study 2 and 3, the median compliance was 99.8% (61.3% – 
100%, range) and 100% (87.1% - 100%), respectively. However, overall compliance to 
placebo treatment was not a significant covariate for the treatment effects on weight. The 
effect of prior treatment in Study 2 and 3 were also investigated as a covariate on the 
treatment effects (    ,    ), but it did not result in an improvement in the model.  
 
Sensitivity analyses 
 When estimated, the MTT parameter increased from 38.9 days to 53 days, 
corresponding to 26% lower estimate of HbA1ckout (0.0566 from 0.0771) and decreased OFV 
by -32.9 points (P <0.001). This resulted in approximately 20-30% lower estimates of the 
effect of post-prandial glucose (PPG) and an increase of 23% on the estimate     (treatment 
effect on β-cell function). Therefore, estimating MTT not only indicates a slower 
glycosylation rate of the red blood cells, but it also shifted the contribution to the production 
of HbA1c from PPG to FPG (Eq. 7, by increasing the estimate of    , insulin and 
consequently FPG). Although this resulted in a significant improvement in the OFV (-24.6 
points, P <0.001), the model was ill-conditioned (eigenvalue number >5000), most likely due 
to the short trial duration for Studies 2 and 3. This parameter was therefore fixed to the 
previously published value of 38.9 days, and the shift in the relative contribution of FPG and 
PPG on the HbA1c was thus not considered. 
  
This article is protected by copyright. All rights reserved. 
 The effect of estimating   was also tested. When estimated, the population estimate 
for   was 0.502 (ΔOFV –26.4 points), which is two-fold higher than the previous estimate of 
0.209 [8]. This corresponds to a reduction in β-cell function by 12%, compared to the 
previous estimate of 5% per year [8]. The effect of removing the treatment effect on -cell 
function (   ) on the estimate of   was tested, however the estimate of    remained high 
(0.562). Factors that may have confounded the estimate of    include the short trial duration 
and the relatively sparse number of FSI observations (4-5 per subject). Since the previous 
estimate of   was based on a long clinical trial with detailed collection of observations (n = 
8587), the population estimate of   was fixed to 0.209 because it is a more plausible estimate 
of disease progression. 
 Model-derived estimates of    and    are shown in Table 4. In contrast to   , there 
were substantial differences in    between studies. When grouped by diabetes duration, the 
disposition index revealed a decrease in the insulin-secretory response in subjects with longer 
diabetes duration, however there was large scatter between the groups (Figure 3). 
Final model evaluation 
The VPCs of the final model showed good agreement between the observations and the 
simulated concentrations between the studies and for each pharmacodynamic measure 
(Figure 2). The final parameter estimates are shown in Table 3. Except for  
   and MTT, all parameters were estimated with acceptable precision (residual standard error 
<30%) without any significant shrinkage (<30%).  
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DISCUSSION 
The most critical factor in the emergence of T2DM is obesity, which reduces insulin 
sensitivity [20]. Diet and exercise is commonly recommended for newly-diagnosed subjects 
with T2DM and can reduce HbA1c by 1.0% [21]. Using the WHIG model, the relationship 
between weight change, insulin sensitivity and ultimately HbA1c can now be described 
mechanistically [8]. Although there are many published disease models for T2DM [22, 23], 
the WHIG model only requires measurements of body weight, FSI, FPG and HbA1c, all of 
which are collected routinely in clinical practice. This is particularly valuable for people with 
a longer history of T2DM who require complex treatment regimens to maintain euglycaemia. 
 In this study we have investigated the effect of applying the WHIG model to a wider 
population of people with T2DM. Although the change in body weight is proportional to the 
change in insulin sensitivity, an inter-study variability parameter for baseline weight was 
required to account for the differences in the median body weight of each study. Subjects 
from Study 1 had experienced the most weight loss (-3.4 [-24.3 to 5.9] kg, median [range]) 
from baseline, and therefore had much larger increases in insulin sensitivity (median increase 
in insulin sensitivity, 23.2%). In contrast, weight loss was not significant in Study 2 (-0.53 [-
9.2 to 4.5] kg) and Study 3 (-1.0 [-7.6 to 9.4] kg) from baseline. Despite this, implementing 
the change in weight as a predictor of insulin sensitivity for Studies 2 and 3 improved the 
model predictions as judged by the objective function value (ΔOFV -34.4) and the agreement 
between the observed and simulated concentrations in FPG (Figure 2).  
 Subjects enrolled in Study 3 were previously treated with metformin but did not have 
a washout phase prior to starting the placebo trial. We have accounted for potential residual 
treatment effects of metformin continuing on in this study, however this did not significantly 
improve the model. Furthermore, the estimated treatment effects (    ,    ) and disease 
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status (  ,   ) were not significantly different between studies. The lack of a washout phase 
for Study 3, therefore was not accounted for in this model because the baseline treatment 
effects were comparable to the estimates from Study 2. It is possible that these subjects were 
no longer responding to the effects of metformin because of the study inclusion criteria 
(inadequately controlled on metformin for over 6 weeks). 
There was very little variability in insulin sensitivity between subjects with T2DM but 
there were substantial differences in -cell function (Table 4). This is in agreement with 
previous studies which had showed very little changes in insulin sensitivity in subjects 
diagnosed with T2DM, but the deterioration in -cell function continued well after the 
diagnosis of T2DM [24, 25]. Subjects from Study 1 had a higher median baseline -cell 
function (57%) compared to Study 2 (39.1%) and Study 3 (30.2%). Since the disease 
progression of -cell function was described using a logistic decay function, subjects with a 
lower baseline -cell function had lower rates of disease progression as it is not possible for 
subjects to have a complete loss of -cell function. Therefore, subjects from Study 3, had the 
slowest rate of -cell function loss (  ), which may be associated with their longer history of 
T2DM. An inter-study variability parameter was required to account for the differences in the 
baseline -cell function. Other covariates, however, were not significant in explaining the 
differences in -cell function.  
Diabetes duration was expected to be a significant covariate for the -cell parameters 
because -cell function typically deteriorates with diabetes duration. However, the variability 
in the diagnosis of T2DM may have confounded diabetes duration as a potential covariate for 
the disease progression parameters, i.e. while some subjects were diagnosed early, others may 
be diagnosed when their diabetes is already quite advanced. The mean time-lapse between 
onset of T2DM to the diagnosis of T2DM can vary up to 6 years [26].  
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In the UKPDS Study, the rate of decline of -cell function was approximately 25% 
over 6 years (about 4% per year) [2, 27]. A model developed using the Belfast Study, 
proposed two phases (Phase A, 1.7%; Phase B, 18.2%) associated with the decline in -cell 
function [24]. This is consistent with the use of the original sigmoid treatment function for 
    (Supplementary Materials) and logistic disease progression function (BF, Eq. 5). 
However when    was estimated, the median rate of loss in baseline β-cell function was 
about 12%, which is much higher than the rate of β-cell function from previous studies [2, 7, 
8, 27].  
We have fixed the estimate of    to previously published values because the estimates 
of    and    are influenced by FSI observations. In our dataset, FSI observations were sparse 
(4-5 observations per subject) compared to the other pharmacodynamic measurements and 
are also influenced by subjects who were not compliant with the fasting protocol. Potential 
outliers can be seen in Figure 3, whereby some subjects had FSI over 60 mI U/L (reference 
range: <30 mI U/L). These outlying FSI observations (and paired FPG concentrations) were 
not excluded due to the significant loss in data (>10%). Furthermore, the shrinkage was low 
when estimating the IIV for    (19%, Table 3). Studies 2 and 3 were also short trials, thus, 
the relationship between diabetes duration and β-cell function may become more apparent 
with the inclusion of people with a longer history of T2DM (>5 years). 
One of the major drawbacks in describing the natural progression of T2DM is the 
need to investigate the untreated population due to the increased risk of diabetic 
complications. The Belfast Study was the only longitudinal study conducted on untreated 
people with T2DM [25]. Long placebo trials are uncommon, particularly in people with 
advanced T2DM. Therefore, future studies with longitudinal data on the treated population 
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may provide more insight on the relationship between disease progression and diabetes 
duration. 
 
Conclusion 
In this study, we have shown that the WHIG model can be applied to a wider 
population of people with T2DM. The change in body weight as a predictor of insulin 
sensitivity was a significant improvement in the model and can also be applied to people who 
are not obese. When the WHIG model was applied to people at varying stages of disease 
severity, large inter-individual variability in the β-cell function was observed but there were 
no statistically significant covariates to explain this variability. Since it is not possible to 
obtain longitudinal data of the untreated population, the application of this model to the 
treated population with a longer history of T2DM is necessary to further investigate the 
relationship between β-cell function and diabetes duration. In future, the disease-modifying 
properties of drugs can be investigated by comparing the treatment effects of antidiabetic 
drugs with the effects of placebo. 
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Table 1. The inclusion criteria and study design of the trials 
 
 Study 1 Study 2  Study 3 
N 181 59 64 
ClinicalTrials.gov 
No. 
NCT0023660 NCT01071850 NCT01117584 
Disease status Treatment 
naïve 
Treatment naïve (n=28) and prior 
treatment (n=31) 
Inadequately 
controlled on a 
daily dose of 1.5 
g metformin (> 
6 weeks) 
BMI (kg/m
2
) 27 – 50 20 - 45 
HbA1c (%)
a
 < 10.5 6.8 – 9.5 7.0 – 9.5 
Diet and exercise 
regimen 
-600kcal diet 
and physical 
activity at all 
visits 
Reported at stable diet and exercise regimen 
throughout the study 
Study design 
Trial duration  66 weeks 14 weeks 
Wash-out phase - - 6 weeks - 
Placebo-run in 6 weeks 2 weeks 
Placebo treatment 
phase 
60 weeks 12 weeks 
Follow-up phase - 4 weeks 
 
a
 As measured at the first clinic visit. 
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Table 2. Baseline characteristics and estimates of subjects from each study. Data are median 
(IQR). 
 
 Study 1 Study 2 
 
Study 3 
 
N 181 66 65 
Age (y) 54 (48 – 60) 55 (48 – 60) 57 (51 - 63) 
% Female  63 56 45  
Height (m) 1.68 (1.62 – 1.77) 1.61 (1.56 – 1.68) 1.68 (1.60 – 1.73) 
BMI (kg/m
2
) 31.8 (29.1 – 35.6) 29.6 (26.6 – 33.8) 31.0 (28.9 – 34.2) 
Baseline 
measurements 
   
Weight (kg) 104.2 (94.3 – 115.4) 79.3 (68.6 – 87.9) 89.0 (81.2 – 97.6)  
FSI (µU/mL)  17.8 (12.3 – 27.4) 12.1 (8.2 – 18.2) 13.4 (9.1 – 21.6) 
FPG (mmol/L)  7.6 (7.0 – 8.5) 7.2 (6.3 – 8.6) 8.5 (7.4 – 10.1) 
HbA1c (%) 6.7 (6.3 – 7.2) 7.4 (7.1 – 7.9) 7.7 (7.2 – 8.2) 
Insulin-to-glucose 
ratio 
2.27 (1.69 – 3.01) 1.51 (1.04 – 2.18) 1.47 (1.10 – 2.44) 
Diabetes duration 
(y)† 
- 2.7 (1.3 – 4.6) 5.8 (2.9 – 8.8) 
 
†Diabetes duration is not known for Study 1 
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Table 3. Final population parameter estimates from the final model. IIV, inter-individual 
variability (%), RSE, residual standard error.  
 
 Parameter estimate 
(RSE%) 
IIV
a
 (RSE%) 
[Shrinkage%] 
Weight   
WGT t1/2 (days) 73.9 (5) - 
Baseline WGT (kg) 102 (1) 16.1 (4) [0] 
β-cell function   
Baseline β-cell function, logistic 
function (  ): 
 
 
Study 1 -0.298 (31) 
1.13 (13) [9.5] 
Study 2 and 3 0.677 (17) 
  , rate of β-cell function loss 
per year, logistic function 
0.209 (fixed) 0.408 (16) [19] 
    , treatment effect on β-
cell function (%) 
0.0781 (31) 0.053 (12) [15.8] 
Insulin sensitivity   
  , baseline insulin sensitivity, 
logistic function 
0.963 (5) 0.485 (13) [6.4] 
      , shape parameter for 
IIV distribution of s0 
-0.476 (15)  - 
ScaleEFS, scaling factor for 
weight change on insulin 
sensitivity 
0.0458 (9) 75.7 (10) [19.9] 
HbA1c   
HbA1c    , %d L/mmol 0.0152 (3) - 
MTT, mean transit time (days) 38.9 (fixed) - 
PPG 0.057 (7) 25.6 (10) [6] 
ScalePPG 0.967 (1)  
Treatment effects   
    , placebo, diet and 
exercise effect at placebo run-
in 
3.0 (16) 
21.3 (16) [12.3]  
    , placebo effect at 
treatment phase (Study 1 only) 
3.46 (16) 28.9 (18) [24.9] 
      , rate of loss of placebo 
treatment effect (% /year) 
3.76 (24) 70.4 (16) [24.1] 
Residual errors   
 Weight 0.0096 (1) - 
 FSI 0.265 (4) 41.5 (6) [22.2] 
 FPG 0.0841 (4) 29 (11.3) [7.2] 
 HbA1c 0.0254 (3) 22 (10) [19.8] 
 
a
Normally distributed IIV (b0,   ,    ,   ,     ,     ,DPR) were reported as absolute values. 
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Table 4. Comparison of the baseline insulin sensitivity and baseline beta-cell function 
parameter estimates of each study. Values are median (IQR). 
 
 Study 1 Study 2 Study 3 
   (%) 24.5 (19.3 – 31.9) 27.4 (20.8 – 43.1) 29.5 (20.1 – 43.1) 
   (%) 57.0 (40.0 – 76.5) 39.1 (25.3 – 59.5) 30.2 (19.0 – 49.2) 
   (logistic function) 0.368 (0.149 – 0.645) 0.369 (0.043 – 0.770) 0.148 (-0.325 – 
0.558) 
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Figure 1. Inter-study variability in placebo arms (Study 1, Study 2 and Study 3). IGR, 
insulin/glucose ratio; B, β-cell function; IS, insulin sensitivity. 
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Figure 2. Visual predictive checks (VPCs) of the observations of weight, fasting serum 
insulin (FSI), fasting plasma glucose (FPG) and HbA1c stratified by study. The shaded areas 
are the 95% confidence intervals of the 10
th
, 50
th
 and 90
th
 percentiles of the simulated 
concentrations. The dotted lines are the 10
th
 and 90
th
 percentiles from the observations and 
the solid line is the 50
th
 percentile of the observations. The dots are the observations. 
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Figure 3. The disposition index of subjects grouped by their diabetes duration. A robust loess 
smooth curve was plotted with a 95% confidence interval around the mean. 
 
